Mergers & Acquisitions ·
On August 27, 2026, argenx SE completed its acquisition of Forte Biosciences Inc. for $77.00 per share in cash
ARGXArgenx SE
On August 27, 2026, argenx SE completed its acquisition of Forte Biosciences Inc. for $77.00 per share in cash. The transaction involved a tender offer and subsequent merger, resulting in argenx owning approximately 87.13% of Forte's outstanding shares immediately following the expiration on August 26, 2026. This acquisition adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to argenx’s immunology pipeline. The company operates as a global immunology innovation company developing novel antibody-based medicines for severe autoimmune diseases.